Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: A case report
- 18 March 2020
- journal article
- case report
- Published by SAGE Publications in Palliative Medicine
- Vol. 34 (6) , 822-825
Abstract
Background: Depressive disorders are common among cancer patients. Ketamine can quickly relieve depression, and its subcutaneous administration appears to be as effective as and probably safer than its standard intravenous administration. Herein, we report a case verifying the antidepressant effect of a subcutaneous esketamine formulation. Case presentation: A 65-year-old male with metastatic abdominal tumor reported sadness, weight loss, fatigue, hopelessness, insomnia, inattention, and reduced motivation. His scores on the visual analogical scale for pain and Montgomery–Asberg depression rating scale were 8/10 and 30/60, respectively. Possible courses of action: Monoaminergic antidepressants are effective, but their response is slow for end-of-life care. Formulation of a plan: Esketamine was preferred because it possibly contributes to pain relief. It can repeatedly be infused intravenously, but was subcutaneously administered twice a week for safety reasons. Outcome: The patient showed continuous mood improvement, achieving depression remission on day 7. Pain relief was observed but without stability. His vital signs remained stable, and he remained calm, without major complaints. Lessons from the case: Repeated subcutaneous esketamine injections are possibly safe and effective in pain and depression relief in palliative care cancer patients. View on research problems, objectives, or questions generated by the case: Placebo-controlled studies with similar cases are needed to establish efficacy and safety.Keywords
This publication has 10 references indexed in Scilit:
- Esketamine for treatment resistant depressionExpert Review of Neurotherapeutics, 2019
- Case Report: Ketamine for Pain and Depression in Advanced CancerJournal of Palliative Medicine, 2018
- Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of AnesthesiologistsRegional Anesthesia & Pain Medicine, 2018
- Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depressionActa Psychiatrica Scandinavica, 2016
- Ketamine enantiomers in the rapid and sustained antidepressant effectsTherapeutic Advances in Psychopharmacology, 2016
- Ketamine for Pain in Adults and Children with Cancer: A Systematic Review and Synthesis of the LiteraturePain Medicine, 2013
- Prevalence of depression in adults with cancer: a systematic reviewAnnals of Oncology, 2012
- Mood and Pain Responses to Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced CancerJournal of Palliative Medicine, 2012
- Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysisPalliative Medicine, 2010
- Intravenous Ketamine “Burst” for Refractory Depression in a Patient with Advanced CancerJournal of Palliative Medicine, 2008